NAICS category

Pharmaceutical Preparation Manufacturing

NAICS 325412

FY2026 ended Sep 30 · data still posting · data as of 2026-11-01†

† DoD contract data posts to USAspending about 90 days after award.

Part of Manufacturing →

$21.2B
Federal awards
FY2026 · data still posting
21
Recipients
NAICS 325412
Code

NAICS code 325412 (Pharmaceutical Preparation Manufacturing) accounted for $21.2B in federal contracts in FY2026, led by the Department of Veterans Affairs, across 21 recipients. Its largest recipient on record was Mckesson Corporation, with 70%. FY2026 ended Sep 30 and its data is still posting. Computed

Obligations by year

Computed
$12.4B
FY20
$22.1B
FY21
$38B
FY22
$16.7B
FY23
$15.9B
FY24
$18.6B
FY25
$21.2B
FY26 partial
▲ 51%
FY20 to FY25

Key takeaways

Computed
FY2026 ended Sep 30 · data still posting · data as of 2026-11-01
  • Pharmaceutical Preparation Manufacturing (NAICS 325412) accounted for $21.2B in federal obligations in FY2026, compared with $18.6B in FY2025.
  • It ranked #11 among industries by federal contract dollars in FY2026 (data still posting).
  • The Department of Veterans Affairs provided 70% of it.
  • Its largest recipient was Mckesson Corporation, with 70%.

Top recipients

Computed

The five largest recipients on record received 94% of this category's FY2026 obligations, and the ten largest 95%.

Mckesson Corporation$14.9B
Merck Sharp & Dohme LLC$2.3B
Pfizer Inc$1.1B
Glaxosmithkline, LLC$1.1B
Sanofi Vaccines US Inc.$734.4M
Emergent Biosolutions Canada Inc$118.3M
Exelan Pharmaceuticals Inc$96.2M
Canadian Commercial Corporation$16.4M
Trillamed LLC$1.1M
Amerisourcebergen Drug Corp$639.4K

Recipient breakdown available for 95% of obligations shown

Awards

Source

Largest FY2026 awards in this category

Awards coded NAICS 325412 that started in FY2026, by the amount obligated on each so far.

AwardIDRecipientObligatedStartEndPlace
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 September36C24026K1012Mckesson Corporation$1.5B2026-09-012026-09-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 November36C24026K1002Mckesson Corporation$1.4B2025-11-012025-11-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 May36C24026K1008Mckesson Corporation$1.4B2026-05-012026-05-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 July36C24026K1010Mckesson Corporation$1.2B2026-07-012026-07-31Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 June36C24026K1009Mckesson Corporation$1.2B2026-06-012026-06-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 April36C24026K1007Mckesson Corporation$1.2B2026-04-012026-04-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 October36C24026K1001Mckesson Corporation$1.2B2025-10-012025-10-31Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 March36C24026K1006Mckesson Corporation$1.2B2026-03-012026-03-31Texas

Largest awards in this category

Award of 10M Treatment Courses of Oral Protease Inhibitor PF-07321332
awarded 2021$12.5B
100M SARS-COV-2 MRNA-1273 Vaccine Doses
awarded 2020$8.2B
COVID-19 Adult MDV Vaccine
awarded 2022$4B
COVID-19 Oral Antiviral MK-4482 (Molnupiravir)
awarded 2021$2.2B
COVID-19 Mrna Vaccines
awarded 2022$1.8B
Express Report: Pharmacy Prime Vendor Cmop FY20 May 1, 2020 to SEP 30, 2020…
awarded 2020$1.7B
COVID-19: Sotrovimab Monoclonal Andtibodies
awarded 2021$1.6B
Vsccine for Children (VFC) 2014
awarded 2014$1.5B

Total value over each award’s life, largest first.

Related

Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.